SLC12A5 and nervous system disorder: Based on the numerous findings that various neurological disease states are accompanied (and perhaps even triggered) by a downregulation of KCC2 and an upregulation of NKCC1, compounds modulating these transporters have been extensively studied in animal models and in several clinical trials (for review see30,31,54).